PMID- 35179741
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220407
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 26
IP  - 3
DP  - 2022 Feb
TI  - Antithrombotic therapy management in a man with ST elevation myocardial 
      infarction and triple positive antiphospholipid syndrome: case report and 
      literature review.
PG  - 755-758
LID - 27983 [pii]
LID - 10.26355/eurrev_202202_27983 [doi]
AB  - OBJECTIVE: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder 
      associated with vascular complications including acute myocardial infarction 
      (AMI). AMI pathogenesis in APS is considered to be acute thrombosis of coronary 
      arteries, in contrast to typical AMI where the pathogenesis is atherosclerotic 
      plaque rupture. Therapeutic management is therefore a clinical challenge. There 
      is no consensus among experts about optimal antithrombotic therapy in secondary 
      prevention. The role of coronary stents is still to be determined, due to the 
      higher rates of stent thrombosis after percutaneous coronary intervention (PCI) 
      in APS patients. CASE REPORT: We described the case of a 51-year-old male, 
      smoker, that presented with anterior ST elevation myocardial infarction (STEMI) 
      as first manifestation of APS. The patient underwent primary PCI on left main and 
      ostial left anterior descending artery. RESULTS: We discussed antithrombotic 
      therapy management after PCI in our patient and reviewed literature on current 
      therapeutic management of this specific population. CONCLUSIONS: APS patients 
      with STEMI should undergo PCI, usually associated with thrombus aspiration, and 
      in select cases stent implantation in the culprit lesion. In the latter case, 
      triple antithrombotic therapy with short-term dual antiplatelet therapy and 
      long-term anticoagulant therapy is recommended. Clinicians should include 
      autoimmune etiologies in the differential diagnosis of underlying causes of AMI.
FAU - Prandi, F R
AU  - Prandi FR
AD  - Division of Cardiology, University of Rome Tor Vergata, Rome, Italy. 
      dalgisio.lecis@gmail.com.
FAU - Milite, M
AU  - Milite M
FAU - Celotto, R
AU  - Celotto R
FAU - Lecis, D
AU  - Lecis D
FAU - Marchei, M
AU  - Marchei M
FAU - Romeo, F
AU  - Romeo F
FAU - Barilla, F
AU  - Barilla F
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - *Antiphospholipid Syndrome/complications/diagnosis/drug therapy
MH  - Fibrinolytic Agents/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myocardial Infarction/diagnosis
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - *ST Elevation Myocardial Infarction/diagnosis/therapy
MH  - Stents/adverse effects
MH  - Treatment Outcome
EDAT- 2022/02/19 06:00
MHDA- 2022/04/08 06:00
CRDT- 2022/02/18 12:15
PHST- 2022/02/18 12:15 [entrez]
PHST- 2022/02/19 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
AID - 27983 [pii]
AID - 10.26355/eurrev_202202_27983 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2022 Feb;26(3):755-758. doi: 
      10.26355/eurrev_202202_27983.